RxDoctor Payments Data

Thomas Facelle, MD

Urology · Golden, CONPI 1114227501

Payments from drug & device makers

$7,127in general payments, 2019–2025

Across 257 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$689
  • Boston Scientific$650
  • Johnson & Johnson$515
  • Teleflex LLC$475
  • Sumitomo Pharma America, Inc.$457
  • Olympus America Inc.$347
  • plus $4K from 45 others

What the payments were for

  • Consulting fees$6709%
  • Food & beverage$6,45791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,127 in reported general payments places this provider in the 70th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$350,970
Medicare patients
375
Services billed
3,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide14$205,509
MyrbetriqMirabegron117$97,074
OrgovyxRelugolix32$84,926
GemtesaVibegron89$72,761
Abiraterone Acetate15$62,997
Testosterone35$5,241
Trospium Chloride56$3,299
Tamsulosin Hcl265$2,692
Finasteride185$2,396
Testosterone Cypionate70$2,031
Desmopressin Acetate31$1,380
Estradiol11$794
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$273
Alfuzosin Hcl ErAlfuzosin Hcl11$258
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$294$302,583131 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$457$157,687121 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$13$62,99715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 urology providers in Colorado.

Other urology in Golden

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →